Extra-articular rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 25, Issue 3, 2013, Pages 360-366

  Turesson, Carl ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

clinical features; epidemiology; interstitial lung disease; rheumatoid arthritis; vasculitis

Indexed keywords

CYCLOPHOSPHAMIDE; METHOTREXATE; METHYLPREDNISOLONE; RITUXIMAB;

ADAPTIVE IMMUNITY; ANTIGEN ANTIBODY COMPLEX; CLINICAL FEATURE; COMORBIDITY; COMPLEMENT ACTIVATION; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; EXTRA ARTICULAR RHEUMATOID ARTHRITIS; FELTY SYNDROME; GLOMERULONEPHRITIS; HUMAN; INTERSTITIAL LUNG DISEASE; MORTALITY; NEUROPATHY; PERICARDITIS; PLEURISY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOID VASCULITIS; SALVAGE THERAPY; SCLERITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; LUNG DISEASES, INTERSTITIAL; PROGNOSIS; SEVERITY OF ILLNESS INDEX; VASCULITIS;

EID: 84875907505     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32835f693f     Document Type: Review

References (65)

1. Turesson C, Matteson EL. Vasculitis in rheumatoid arthritis. Curr Opin Rheumatol 2009; 21:35-40.
2. Turesson C, Matteson EL. Rheumatoid arthritis and other synovial disorders. Extraarticular features of rheumatoid arthritis and systemic involvement. In: Hochberg M, editor. Rheumatology. 5th ed. London: Elsevier; 2011.
3. Prete M, Racanelli V, Digiglio L, et al. Extra-articular manifestations of rheumatoid arthritis: an update. Autoimmun Rev 2011; 11:123-131.
4. Turesson C, Matteson EL. Management of extra-articular disease manifestations in rheumatoid arthritis. Curr Opin Rheumatol 2004; 16:206-211.
5. Turesson C. Management of rheumatoid arthritis: the patient with extraarticular disease. In: Weisman W, Louie, van Vollenoven, editors. Targeted therapies of rheumatic diseases. 1st ed. Philadelphia: Saunders; 2010.
6. Gordon DA, Stein JL, Broder I. The extra-articular features of rheumatoid arthritis: a systematic analysis of 127 cases. Am J Med 1973; 54:445-452.
7. Nyhall-Wahlin BM, Jacobsson LT, Petersson IF, Turesson C. Smoking is a strong risk factor for rheumatoid nodules in early rheumatoid arthritis. Ann Rheum Dis 2006; 65:601-606.
8. Turesson C, Jacobsson LT. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 2004; 33:65-72.
9. Turesson C, McClelland RL, Christianson T, Matteson E. Clustering of extraarticular manifestations in patients with rheumatoid arthritis. J Rheumatol 2008; 35:179-180.
10. Turesson C, Jacobsson L, Bergstrom U, et al. Predictors of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 2000; 29:358-364.
11. Nyhall-Wahlin BM, Petersson IF, Nilsson JA, et al. High disease activity disability burden and smoking predict severe extra-articular manifestations in early rheumatoid arthritis. Rheumatology (Oxford) 2009; 48:416-420.
12. Turesson C, Jacobsson L, Bergstrom U. Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology (Oxford) 1999; 38:668-674.
13. Turesson C, O'Fallon WM, Crowson CS, et al. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002; 29:62-67.
14. Turesson C, McClelland RL, Christianson TJ, Matteson EL. No decrease over time in the incidence of vasculitis or other extraarticular manifestations in rheumatoid arthritis: results from a community-based study. Arthritis Rheum 2004; 50:3729-3731.
15. Watts RA, Mooney J, Lane SE, Scott DG. Rheumatoid vasculitis: becoming extinct Rheumatology (Oxford) 2004; 43:920-923.
16. Myasoedova E, Crowson CS, Turesson C, et al. Incidence of extraarticular rheumatoid arthritis in Olmsted County Minnesota, in 1995-2007 versus 1985-1994: a population-based study. J Rheumatol 2011; 38:983-989.
17. Bartels CM, Bell CL, Shinki K, et al. Changing trends in serious extra-articular manifestations of rheumatoid arthritis among United State veterans over 20 years. Rheumatology (Oxford) 2010; 49:1670-1675.
18. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69:631-637.
19. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs. Ann Rheum Dis 2010; 69:964-975.
20. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64:625-639.
21. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30:1205-1213.
22. Gorman JD, Lum RF, Chen JJ, et al. Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3240 rheumatoid arthritis patients. Arthritis Rheum 2004; 50:400-412.
23. Gorman JD, David-Vaudey E, Pai M, et al. Particular HLA-DRB1 shared epitope genotypes are strongly associated with rheumatoid vasculitis. Arthritis Rheum 2004; 50:3476-3484.
24. Turesson C, Schaid DJ, Weyand CM, et al. The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis. Arthritis Res Ther 2005; 7:R1386-R1393.
25. Turesson C, Schaid DJ, Weyand CM, et al. Association of HLA-C3 and smoking with vasculitis in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:2776-2783.
26. Jarrett SJ, Cunnane G, Conaghan PG, et al. Antitumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 2003; 30:2287-2291.
27. Chatterjee S. Severe interstitial pneumonitis associated with infliximab therapy. Scand J Rheumatol 2004; 33:276-277.
28. Lindsay K, Melsom R, Jacob BK, Mestry N. Acute progression of interstitial lung disease: a complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment. Rheumatology (Oxford) 2006; 45:1048-1049.
29. Wolfe F, Caplan L, Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol 2007; 36:172-178.
30. Nyhall-Wahlin BM, Petersson I, Jacobsson C, et al. Extra-articular manifestations in a community-based sample of patients with rheumatoid arthritis: incidence and relationship to treatment with TNF inhibitors. Scand J Rheumatol 2012; 41:434-437.
31. Erhardt CC, Mumford PA, Venables PJ, Maini RN. Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis 1989; 48:7-13.
32. Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003; 48:54-58.
33. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52:722-732.
34. Turesson C, McClelland RL, Christianson TJ, Matteson EL. Severe extraarticular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66:70-75.
35. Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46:2294-2300.
36. Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010; 62:2625-2632.
37. Turesson C, McClelland RL, Christianson TJ, Matteson EL. Multiple extraarticular manifestations are associated with poor survival in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65:1533-1534.
38. Martens PB, Pillemer SR, Jacobsson LT, et al. Survivorship in a population based cohort of patients with Sjogren's syndrome 1976-1992. J Rheumatol 1999; 26:1296-1300.
39. Erhardt CC, Mumford P, Maini RN. The association of cryoglobulinaemia with nodules, vasculitis and fibrosing alveolitis in rheumatoid arthritis and their relationship to serum C1q binding activity and rheumatoid factor. Clin Exp Immunol 1979; 38:405-413.
40. Michel JJ, Turesson C, Lemster B, et al. CD56-expressing T cells that have features of senescence are expanded in rheumatoid arthritis. Arthritis Rheum 2007; 56:43-57.
41. Campion G, Maddison PJ, Goulding N, et al. The Felty syndrome: a casematched study of clinical manifestations and outcome, serologic features, and immunogenetic associations. Medicine (Baltimore) 1990; 69:69-80.
42. Mageed RA, Kirwan JR, Thompson PW, et al. Characterisation of the size and composition of circulating immune complexes in patients with rheumatoid arthritis. Ann Rheum Dis 1991; 50:231-236.
43. Geirsson AJ, Sturfelt G, Truedsson L. Clinical and serological features of severe vasculitis in rheumatoid arthritis: prognostic implications. Ann Rheum Dis 1987; 46:727-733.
44. Turesson C, Eberhardt K, Jacobsson LT, Lindqvist E. Incidence and predictors of severe extra-articular disease manifestations in an early rheumatoid arthritis inception cohort. Ann Rheum Dis 2007; 66:1543-1544.
45. Puechal X, Said G, Hilliquin P, et al. Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis: a clinicopathologic and prognostic study of thirty-two patients. Arthritis Rheum 1995; 38:1618-1629.
46. Voskuyl AE, Zwinderman AH, Westedt ML, et al. Factors associated with the development of vasculitis in rheumatoid arthritis: results of a case-control study. Ann Rheum Dis 1996; 55:190-192.
47. Turesson C, Jacobsson LT, Sturfelt G, et al. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 2007; 66:59-64.
48. Atkins SR, Turesson C, Myers JL, et al. Morphologic and quantitative assessment of CD20\+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum 2006; 54:635-641.
49. Turesson C, Matteson EL, Colby TV, et al. Increased CD4\+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. Arthritis Rheum 2005; 52:73-79.
50. Furukawa H, Oka S, Shimada K, et al. Association of human leukocyte antigen with interstitial lung disease in rheumatoid arthritis: a protective role for shared epitope. PLoS One 2012; 7:e33133.
51. Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med 1984; 76:377-384.
52. Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology 1984; 91:1253-1263.
53. Ropes MW, Bennett GA, Cobb S, et al. 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958; 9:175-176.
54. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-324.
55. Puechal X, Miceli-Richard C, Mejjad O, et al. Antitumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. Ann Rheum Dis 2008; 67:880-884.
56. Puechal X, Gottenberg JE, Berthelot JM, et al. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: results from the autoimmunity and rituximab registry. Arthritis Care Res (Hoboken) 2012; 64:331-339.
57. Kim DS. Interstitial lung disease in rheumatoid arthritis: recent advances. Curr Opin Pulm Med 2006; 12:346-353.
58. Berglund K, Keller C, Thysell H. Alkylating cytostatic treatment in renal amyloidosis secondary to rheumatic disease. Ann Rheum Dis 1987; 46:757-762.
59. Nakamura T, Higashi S, Tomoda K, et al. Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Exp Rheumatol 2007; 25:518-522.
60. Vassallo R, Matteson E, Thomas CF Jr. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest 2002; 122:1093-1096.
61. Kuroki M, Noguchi Y, Shimono M, et al. Repression of bleomycin-induced pneumopathy by TNF. J Immunol 2003; 170:567-574.
62. Distler JH, Schett G, Gay S, Distler O. The controversial role of tumor necrosis factor alpha in fibrotic diseases. Arthritis Rheum 2008; 58:2228-2235.
63. Dixon WG, Hyrich KL, Watson KD, et al. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010; 69:1086-1091.
64. Ogawa D, Hashimoto H, Wada J, et al. Successful use of cyclosporin A for the treatment of acute interstitial pneumonitis associated with rheumatoid arthritis. Rheumatology (Oxford) 2000; 39:1422-1424.
65. Scott DG, Bacon PA. Response to methotrexate in fibrosing alveolitis associated with connective tissue disease. Thorax 1980; 35:725-731.